Results 31 to 40 of about 13,925,210 (307)

Second-Line Treatment of Ovarian Cancer [PDF]

open access: yesThe Oncologist, 2000
Abstract Patients with epithelial ovarian cancer are often diagnosed with advanced-stage disease. Although clinical complete remissions are obtained in the majority of patients through a combination of cytoreductive surgery and chemotherapy, relapse is common.
M, Markman, M A, Bookman
openaire   +2 more sources

Second-line Antiretriviral Therapy in Northern Tanzania [PDF]

open access: yes, 2014
Following rapid expansion of anti-retroviral therapy (ART) in resource limited settings, some patients are failing and require switching to second line ART.
Omari, Habib
core   +1 more source

Retrospective Analysis of Donor Lymphocyte Infusions in Pediatric Patients With Mixed Chimerism After Hematopoietic Stem Cell Transplantation

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an essential therapy for several malignant and nonmalignant diseases, but relapse and graft loss remain the principal threats to its success. Routine monitoring of chimerism and minimal residual disease (MRD) enables early detection of imminent recurrence and guides ...
Carmen Junk   +10 more
wiley   +1 more source

Second-line therapies in immune thrombocytopenia [PDF]

open access: yesHematology, 2016
Abstract Immune thrombocytopenia (ITP) is a rare, acquired autoimmune condition characterized by a low platelet count and an increased risk of bleeding. Although many children and adults with ITP will not need therapy beyond historic first-line treatments of observation, steroids, intravenous immunoglobulin (IVIG), and anti-D globulin,
Rachael F, Grace, Cindy, Neunert
openaire   +2 more sources

Assessing the association between changing NRTIs when initiating second-line ART and treatment outcomes. [PDF]

open access: yes, 2018
BACKGROUND After first-line antiretroviral therapy (ART) failure, the importance of change in nucleoside reverse transcriptase inhibitor (NRTI) in second-line is uncertain due to the high potency of protease inhibitors used in second-line. SETTING
Horsburgh, C Robert   +41 more
core   +2 more sources

Referral Patterns and Diagnostic Timeliness in Pediatric Cancer: A Hospital‐Based Study in Indonesia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Timely diagnosis and treatment are critical for improving survival among children with cancer. In low‐ and middle‐income countries (LMICs), delays are common and may be influenced by fragmented referral pathways and diagnostic limitations.
Nur Melani Sari   +5 more
wiley   +1 more source

Direct mass spectrometry analysis of biological tissue for diagnosis of thyroid cancer using wooden-tip electrospray ionization

open access: yesFrontiers in Chemistry, 2023
Direct mass spectrometry (MS) analysis of human tissue at the molecular level could gain insight into biomarker discovery and disease diagnosis. Detecting metabolite profiles of tissue sample play an important role in understanding the pathological ...
Dasheng Liu   +10 more
doaj   +1 more source

Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa [PDF]

open access: yes, 2012
To measure rates and predictors of virologic failure and switch to second-line antiretroviral therapy (ART) in South ...
Olivia Keiser   +36 more
core   +3 more sources

Venetoclax‐Based Therapy as a Bridge to Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Pediatric Acute Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Relapsed and/or refractory (R/R) pediatric acute leukemia carries a dismal prognosis, largely driven by chemoresistance to conventional salvage therapy. The BH3‐mimetic venetoclax, combined with chemotherapy or hypomethylating agents, has demonstrated efficacy in small clinical trials.
Katherine S. Colman   +9 more
wiley   +1 more source

SAGA—a phase Ib/II single-arm, multicenter study of sacituzumab govitecan for patients with metastatic esophagogastric adenocarcinoma

open access: yesESMO Gastrointestinal Oncology
Background: Treatment of metastatic and locally advanced unresectable esophagogastric adenocarcinoma (EGA) after first-line therapy has limited efficacy. Sacituzumab govitecan (SG) is an antibody-drug conjugate (ADC) linking a TROP-2-directed antibody to
B. Kobitzsch   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy